Scarica l'app Stockscreener
7.40
2.89%
-0.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.62
Aprire:
$7.65
Volume 24 ore:
5.92M
Relative Volume:
1.17
Capitalizzazione di mercato:
$1.56B
Reddito:
$557.51M
Utile/perdita netta:
$-35.71M
Rapporto P/E:
-41.11
EPS:
-0.18
Flusso di cassa netto:
$15.50M
1 W Prestazione:
-1.33%
1M Prestazione:
-3.14%
6M Prestazione:
-18.32%
1 anno Prestazione:
-8.07%
Intervallo 1D:
$7.38
$8.04
Intervallo di 1 settimana:
$7.2125
$8.05
Portata 52W:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Confronta BCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.40 | 1.61B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Ripresa | TD Cowen | Buy |
| 2025-10-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Iniziato | Wedbush | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
FDA approves seven NMEs in December - biocentury.com
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack - Investing.com Nigeria
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack By Investing.com - Investing.com South Africa
BioCryst Raises Price of Key ORLADEYO Treatment - TipRanks
Is BioCryst Pharmaceuticals Inc. stock oversold or undervalued2025 Trading Recap & AI Forecasted Entry and Exit Points - ulpravda.ru
How BioCryst Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - ulpravda.ru
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsGap Down & Free Verified High Yield Trade Plans - ulpravda.ru
CEO Moves: Will BioCryst Pharmaceuticals Inc. stock deliver long term returnsPortfolio Update Report & Expert Verified Movement Alerts - ulpravda.ru
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Yahoo Finance
RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating - MarketScreener
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - The Malaysian Reserve
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Liquidity Mapping Around (BCRX) Price Events - Stock Traders Daily
Will BioCryst Pharmaceuticals Inc. stock beat EPS estimatesRisk Management Strategies & Invest Smarter With Signals - bollywoodhelpline.com
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
Charlie Gayer to be BioCryst CEO effective January 1 - The Pharma Letter
BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says - marketscreener.com
Rice Hall James & Associates LLC Sells 179,891 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
Trade Report: Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zone2025 Market Sentiment & Advanced Technical Signal Analysis - moha.gov.vn
Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks
Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets
1-year trial data: Orladeyo cuts swelling attacks in young children - Angioedema News
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Insider Monkey
Is BioCryst Pharmaceuticals Inc. stock supported by strong fundamentalsBond Market & Short-Term High Return Strategies - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve
Published on: 2025-12-19 20:19:26 - ulpravda.ru
Will BioCryst Pharmaceuticals Inc. stock deliver strong dividend growthGold Moves & Free Community Supported Trade Ideas - DonanımHaber
What is the fair value of BioCryst Pharmaceuticals Inc. stock now2025 Support & Resistance & Safe Capital Growth Stock Tips - DonanımHaber
ETF Watch: What is the fair value of BioCryst Pharmaceuticals Inc. stock now2025 Support & Resistance & Safe Capital Growth Stock Tips - DonanımHaber
EDGAR Filing Documents for 0001140361-25-046040 - SEC.gov
Astria Therapeutics (NASDAQ: ATXS) details terms of BioCryst merger and special vote - Stock Titan
BioCryst Pharmaceuticals (BCRX) details cash and stock deal to acquire Astria - Stock Titan
Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zone2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
Published on: 2025-12-18 17:50:37 - ulpravda.ru
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (BCRX) officer reports 8,181-share tax withholding - Stock Titan
Q4 Earnings Estimate for BCRX Issued By HC Wainwright - MarketBeat
BioCryst Pharmaceuticals (BCRX) CLO reports tax withholding and share sale - Stock Titan
CEO Stonehouse Surrenders 27,368 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView — Track All Markets
BioCryst Pharmaceuticals (NASDAQ: BCRX) CEO reports tax share withholding - Stock Titan
BioCryst Pharma stock price target raised to $32 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Bullish Estimate for BCRX FY2025 Earnings - MarketBeat
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? - Yahoo Finance
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):